In this presentation, Dr. Azza Idris will discuss how insights from protective human monoclonal antibodies are informing the development of next-generation malaria vaccines, including approaches to designing immunogens that target conserved sites of vulnerability on P. falciparum.

In this presentation, Dr. Goodarz Danaei will discuss emerging approaches to cardiovascular risk prediction and prevention, including the use of causal inference methods and nationally representative data to develop more accurate risk models. He will explore the limitations of existing prediction tools, which often rely on outdated cohort studies or nonrepresentative electronic medical record data, and present new research aimed at improving population-level prevention strategies in the United States and globally.

This session examines the state of AI in global health through a central question: What structural challenges does global health face, which of those can AI realistically help address, under what conditions, and where does hype outpace the evidence?

As artificial intelligence becomes increasingly embedded in health systems, how can we know whether these tools are delivering meaningful health benefits? AI tools can be updated and redeployed faster than the evidence validating them, raising the question of whether current evaluation frameworks are built for the speed of adoption. This session explores what rigorous impact assessments for AI tools should address.

In this presentation, Dr. Rebbeck will offer an exposition of the problems and suggestions to address them. Examples include the development of research and clinical translation by the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network that builds an African knowledge base around factors driving prostate cancer disparities in Africa. Additional initiatives like the African Oncogenetics Network and the STARS Training Program further enhance research capacity by training African scientists, establishing biobanks, supporting mentorship, and ensuring sustainable, high-impact cancer research infrastructure that benefits both African communities and the global scientific community.